Skip to content
Open access

Autocrine PD-1-blocking nanobodies enhance the antitumor efficacy of TCR-like CAR-T cells by attenuating t cell exhaustion

Aug 2026 · Journal of Translational Medicine · Vol 24 · 0 citations · 40 references
Medicine

TL;DR

In the SKOV3-A2 solid tumor xenograft model, WT1-CAR-Nb T cells mediated superior tumor growth control and significantly prolonged overall survival, which was closely correlated with enhanced intratumoral T cell infiltration and persistent in vivo expansion of engineered T cells.

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematologic malignancies, but its efficacy against solid tumors is severely limited by two core barriers: the scarcity of uniformly expressed tumor-associated antigens (TAAs) and the immunosuppressive tumor microenvironment (TME), in which PD-1/PD-L1 signaling promotes irreversible T cell exhaustion. This study aimed to develop a novel T cell receptor-mimic (TCRm) CAR-T platform with autocrine anti-PD-1 nanobody secretion to simultaneously overcome antigen heterogeneity and TME immunosuppression. A lentiviral vector encoding a TCRm CAR targeting HLA-A*02:01-restricted WT1 and a secreted anti-PD-1 nanobody was constructed to generate WT1-CAR-Nb T cells. WT1-CAR T cells (CAR-only control) and Mock T cells were also prepared. In vitro assays included antigen-specific cytotoxicity, proinflammatory cytokine (IFN-γ, TNF-α) detection, chronic antigen stimulation-induced T cell exhaustion model, and transcriptomic analysis. In vivo efficacy was evaluated in human ovarian cancer SKOV3-A2 xenograft mice via tumor growth monitoring, survival analysis, intratumoral T cell infiltration assessment, and safety evaluation. WT1-CAR-Nb T cells targeting the HLA-A*02:01-restricted WT1 and constitutively secreting anti-PD-1 nanobody were successfully generated. In vitro functional assays demonstrated that WT1-CAR-Nb T cells exhibited significantly enhanced antigen-specific cytotoxicity and secreted markedly higher levels of proinflammatory cytokines IFN-γ and TNF-α compared with conventional WT1-CAR T cells upon specific antigen stimulation. Critically, autocrine PD-1 nanobody blockade effectively alleviated TME immunosuppression, as reflected by downregulated expression of multiple exhaustion markers (TIM-3, CTLA-4, TIGIT) and preserved proliferative potential under chronic antigen stimulation. In the SKOV3-A2 solid tumor xenograft model, WT1-CAR-Nb T cells mediated superior tumor growth control and significantly prolonged overall survival, which was closely correlated with enhanced intratumoral T cell infiltration and persistent in vivo expansion of engineered T cells. Local autocrine PD-1 checkpoint blockade potently enhances the effector function and durability of TCRm CAR-T cells. This armored TCRm CAR-T strategy is a promising therapeutic approach for solid tumor immunotherapy, with broad translational potential for other TCRm CAR systems targeting distinct peptide-MHC epitopes.

Read PDF

Similar papers

Antitumor activities of chimeric antigen receptor t cells targeting mucin-1 with self-secreting anti PD-1 IgG antibody

The engineering of CAR T cells to secrete an anti PD-1 antibody enhances therapeutic efficacy compared to second-generation CAR T cells, and this improvement is partly attributed to enhanced T cell proliferation and reduced PD-1 expression following repeated antigen stimulation.

Nattarika Khuisangeam · 0 citations
Open access Sep 2026

IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8+ T cells while restraining regulatory T-cell accumulation

Abstract Background Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8+ T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade. Methods Using the mouse IL-2/CD25 fusion protein (mIL-2/CD25) at a high dose (HD) and a...

Kathryn M. Laporte, Janika Põder, D. Ivanova et al. · 0 citations
Open access Sep 2026

17 Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment

Anti-CAIX/CD70 DFIR CAR-T cell therapy simultaneously addresses three critical barriers to solid tumor immunotherapy — antigen heterogeneity, OTOT toxicity, and TME immunosuppression — and holds promise to achieve durable cures for advanced RCC.

Yu-Fei Wang · 0 citations
Open access Aug 2026

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1

In vitro data revealed that a bispecific antibody simultaneously engaging PD-L1 and CD38 exhibited markedly enhanced antitumor efficacy—even under conditions of reduced CD38 surface expression on MM cells.

Chaofan Wang, Wanting Wang, Mo-Ran Wang et al. · 0 citations
Open access Aug 2026

IL-12 restores the sequential cytotoxic capacities of anti-GD2 CAR-T and CAR-iNKT cells against glioblastoma

The mechanisms through which GBM cells evade GD2-targeted CAR-T and CAR-iNKT cells effectively target GBM but are susceptible to repeated antigen exposure, which IL-12 could counteract, and encourage further development of armored IL-12 CAR-T or CAR-iNKT cells.

Tan-Dai Tran, Cindy Lamorlette, Loris Gerard et al. · 0 citations
Aug 2026

P1.055. Combination of CAR-T Cell Therapy With Immune Checkpoint Inhibition Enhances Anti-Tumor Efficacy in Esophageal Squamous Cell Carcinoma

Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Chimeric antigen receptor (CAR)-T cell therapy has limited efficacy in solid tumors like esophageal squamous cell carcinoma (ESCC). This study investigates whether combining CAR-T cells with an anti-PD-1 antibody can overcome immunosuppression and impr...

Ning Zhao · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.